AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 211 min read$SEER

Seer’s finance chief will leave Oct. 1. A company finance VP will take over.

Seer (SEER) announced that CFO David Horn will leave on October 1, 2026, to join a private company. Charles Endweiss, VP of Financial Planning & Analysis, will take over as Treasurer and principal financial officer on the same date. The CEO praised Horn's contributions and Endweiss's expertise.

Original reporting
stocktitan.net
Published Sep 21, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

The CFO transition is a routine leadership change with limited immediate financial impact but could influence future strategic decisions.

02

Market read

The announcement is a primary disclosure of an executive change, modest relevance for traders monitoring Seer.

03

What to watch

Potential hidden cost synergies or strategic shifts under the new CFO are not disclosed.

Relevance 5/10Novelty 6/10Timing: effective Oct 1, 2026

Background

Seer is a Nasdaq‑listed proteomics company that provides deep, unbiased proteomic insights.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Seer announced that CFO David Horn will depart on Oct. 1, 2026 and VP Charles Endweiss will assume the CFO role.

Expected impact

Potential modest price movement around the announcement; no immediate directional bias.

Evidence & confidence

Executive changes are material but the company is small and the transition is internal, limiting market impact.

Market effects

Sector

Minimal; the proteomics sector may note a leadership change but no broader impact.

Regional

None; company is US‑based with limited regional exposure.

Global

Low; no global market shift expected.

Counterpoint

What could challenge this read

The CFO departure could be seen as a risk if the new CFO lacks experience in capital markets.

Key entities

  • executive
    David Horn

    Outgoing President, CFO and Treasurer.

  • executive
    Charles Endweiss

    Incoming CFO, previously VP of FP&A.

Read at source← All news

Related articles

AUG 14
$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

sci-tech-today.com6 min
AUG 11
$SEERMedAI 8/10

Seer Reports Second Quarter 2026 Financial Results

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial r

SEC EDGAR 8-K6 min
JUL 30
$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

stocktitan.net4 min
JUL 7
$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

rttnews.com6 min